EUROPEAN COMMISSION

Brussels, 27.5.2025
C(2025) 3573 final

PUBLIC VERSION

Cooper Consumer Health S.A.S
Place Lucien Auvert
77 000 Melun
France

Subject: **Case M.11961 – COOPER / VIATRIS (OVER THE-COUNTER ASSETS)**
Commission decision pursuant to Article 6(1)(b) of Council Regulation (EC) No 139/2004 ([1]) and Article 57 of the Agreement on the European Economic Area ([2])

Dear Sir or Madam,

(1) On 2 May 2025, the European Commission received notification of a proposed concentration pursuant to Article 4 of the Merger Regulation, by which Cooper Consumer Health S.A.S. ("Cooper", France) will acquire, within the meaning of Article 3(1)(b) of the Merger Regulation, sole control of the whole of the assets of the European over-the-counter ("OTC") business of Viatris Inc. (the "Target", France and Italy). The concentration is accomplished by way of purchase of assets. ([3])

(2) The business activities of the undertakings concerned are the following:

– Cooper is a consumer healthcare company principally active in the manufacturing and distribution of OTC, consumer health and consumer self-care products,

– the Target consists of a small number of OTC products, including a medical device for cutting pills, laxatives, vitamins and caffeine tablets.

(3) After examination of the notification, the European Commission has concluded that the notified operation falls within the scope of the Merger Regulation and of

([1]) OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation'). With effect from 1 December 2009, the Treaty on the Functioning of the European Union ('TFEU') has introduced certain changes, such as the replacement of 'Community' by 'Union' and 'common market' by 'internal market'. The terminology of the TFEU will be used throughout this decision.
([2]) OJ L 1, 3.1.1994, p. 3 (the 'EEA Agreement').
([3]) OJ C, C/2025/2759, 14.05.2025.

paragraph 5(d) of the Commission Notice on a simplified treatment for certain concentrations under Council Regulation (EC) No 139/2004. ([4])

(4) For the reasons set out in the Notice on a simplified treatment, the European Commission has decided not to oppose the notified operation and to declare it compatible with the internal market and with the EEA Agreement. This decision is adopted in application of Article 6(1)(b) of the Merger Regulation and Article 57 of the EEA Agreement.

For the Commission

(Signed)
Olivier GUERSENT
Director-General
Directorate-General for Competition

([4]) OJ C 160, 5.5.2023, p. 1 (the 'Notice on a simplified treatment').